^
    Back
    Association details:
    Biomarker:KRAS exon 2 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:erlotinib (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer

    Excerpt:
    ...Phase 2: Correlation of KRAS mutations (in exons 2 and 3) in the original tumor tissue with treatment response and outcome....
    Trial ID:
    NCT00707252
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    PLoS Med
    Title:

    KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

    Excerpt:
    These results have important clinical implications. First, they extend previous data from our group and others showing that lung adenocarcinomas containing EGFR mutations are associated with sensitivity to gefitinib or erlotinib (17 of 17 in this series; 100% observed response rate; 95% CI, 82%–100%). Second, these data show that tumors with KRAS exon 2 mutations (n = 9) are associated with a lack of response to these kinase inhibitors (0% observed response rate; 95% CI, 0%–30%).
    DOI:
    10.1002/cncr.28561